scholarly journals PURIFICATION OF A XYLANASE FROM Penicillium crustosum AND ITS POTENTIAL USE IN CLARIFYING FRUIT JUICE

2019 ◽  
pp. 91-100
Author(s):  
Jaina Caroline Lunkes ◽  
Vanessa Cristina Arfelli ◽  
Jorge William Fischdick Bittencourt ◽  
Rafael Andrade Menolli ◽  
Alexandre Maller ◽  
...  
Keyword(s):  
Fruit Juice ◽  
Penicillium Crustosum ◽  
Potential Use

Penicillium crustosum. [Descriptions of Fungi and Bacteria].

2003 ◽  
Author(s):  
Z. Kozakiewicz
Keyword(s):  
Geographical Distribution ◽  
Geographic Distribution ◽  
World Wide ◽  
Fruit Juice ◽  
Poultry Litter ◽  
Copper Electroplating ◽  
Penicillium Crustosum ◽  
Temperate Climates

Abstract A description is provided for Penicillium crustosum. Information is included on the disease caused by the organism, its transmission, geographical distribution, and hosts. HOSTS: Although primarily considered to be a weak pathogen of pomaceous fruits, the species is an ubiquitous spoilage organism, particularly in cereals and compound feedstuffs, and probably also on decaying vegetation in temperate climates (PITT & HOCKING, 1997). Penicillium crustosum has also been isolated from cheese, blueing powder for cheese, fruit juice, thyme, cassava, citrus, copper electroplating solution, PVA emulsion, poultry litter, soil and tobacco (CABI BIOSCIENCE, 1999). DISEASES: It is considered to be a weak pathogen of pomaceous fruits, particularly apples (SANDERSON & SPOTTS, 1995). GEOGRAPHIC DISTRIBUTION: World-wide, but more commonly isolated in temperate climates.

Biological Control of Peach Fungal Pathogens by Commercial Products and Indigenous Yeasts

2006 ◽  
Vol 69 (10) ◽  
pp. 2465-2470 ◽  
Author(s):  
CRISTINA RESTUCCIA ◽  
FRANCESCO GIUSINO ◽  
FABIO LICCIARDELLO ◽  
CINZIA RANDAZZO ◽  
CINZIA CAGGIA ◽  
...  
Keyword(s):  
Fungal Pathogens ◽  
Mucor Circinelloides ◽  
Antagonistic Activity ◽  
Yeast Cells ◽  
Penicillium Crustosum ◽  
Indigenous Yeasts ◽  
Pichia Kluyveri ◽  
Different Levels ◽  
Potential Use

The potential use of the commercial biocontrol products Serenade (Bacillus subtilis QST-713) and Trichodex (Trichoderma harzianum Rifai strain T39) to inhibit the postharvest pathogenic molds Penicillium crustosum and Mucor circinelloides was investigated. Both products exhibited antagonistic activity in vitro against the pathogens, reducing their growth at different levels. In addition, epiphytic yeasts isolated from peaches were identified as Candida maltosa, Pichia fermentans, and Pichia kluyveri by PCR–restriction fragment length polymorphism of internal transcribed spacer regions and screened for antagonistic activity against the same molds. The efficacy of biocontrol in vitro was dependent on the concentration of the yeast cells. Optimal yeast concentrations were above 107 CFU ml−1. However, C. maltosa and P. fermentans were more effective than P. kluyveri in inhibiting molds. The exclusion of antifungal metabolite production and direct competition for nutrients or space with the pathogens was proposed as the mechanism of biocontrol. Application of biocontrol agents directly on artificially wounded peach fruits significantly reduced the incidence of mold rot during storage at 20°C.

The growth of mica polytypes as studied by conventional and high-resolution TEM

1983 ◽  
Vol 41 ◽  
pp. 174-177
Author(s):  
A. Baronnet ◽  
M. Amouric
Keyword(s):  
Water Pressure ◽  
Point Of View ◽  
Temperature Fields ◽  
Natural Occurrence ◽  
Growth Mechanisms ◽  
Long Period ◽  
High Resolution Tem ◽  
Layer Stacking ◽  
Experimental Works ◽  
Potential Use

The origin of mica polytypes has long been a challenging problem for crystal- lographers, mineralogists and petrologists. From the petrological point of view, interest in this field arose from the potential use of layer stacking data to furnish further informations about equilibrium and/or kinetic conditions prevailing during the crystallization of the widespread mica-bearing rocks. From the compilation of previous experimental works dealing with the occurrence domains of the various mica "polymorphs" (1Mr, 1M, 2M1, 2M2 and 3T) within water-pressure vs temperature fields, it became clear that most of these modifications should be considered as metastable for a fixed mica species. Furthermore, the natural occurrence of long-period (or complex) polytypes could not be accounted for by phase considerations. This highlighted the need of a more detailed kinetic approach of the problem and, in particular, of the role growth mechanisms of basal faces could play in this crystallographic phenomenon.

An atomic-resolution microscope study of Al contracts on GaAs

1986 ◽  
Vol 44 ◽  
pp. 726-727
Author(s):  
Z. Liliental-Weber ◽  
C. Nelson ◽  
R. Ludeke ◽  
R. Gronsky ◽  
J. Washburn
Keyword(s):  
High Speed ◽  
Schottky Contacts ◽  
Detailed Knowledge ◽  
The Past ◽  
Semiconductor Interfaces ◽  
Deposited Metal ◽  
Microwave Applications ◽  
Free Interfaces ◽  
Potential Use

The properties of metal/semiconductor interfaces have received considerable attention over the past few years, and the Al/GaAs system is of special interest because of its potential use in high-speed logic integrated optics, and microwave applications. For such materials a detailed knowledge of the geometric and electronic structure of the interface is fundamental to an understanding of the electrical properties of the contact. It is well known that the properties of Schottky contacts are established within a few atomic layers of the deposited metal. Therefore surface contamination can play a significant role. A method for fabricating contamination-free interfaces is absolutely necessary for reproducible properties, and molecularbeam epitaxy (MBE) offers such advantages for in-situ metal deposition under UHV conditions

The potential use of short chain peptides in parenteral nutrition

1985 ◽  
Vol 4 ◽  
pp. 116-123 ◽  
Author(s):  
P STEHLE ◽  
S ALBERS ◽  
I AMBERGER ◽  
P PFAENDER ◽  
P FURST
Keyword(s):  
Parenteral Nutrition ◽  
Short Chain ◽  
Potential Use

Instant 99mTc Compounds

1971 ◽  
Vol 10 (03) ◽  
pp. 245-251 ◽  
Author(s):  
P. Richards ◽  
W. C. Eckelman
Keyword(s):  
Physical Properties ◽  
High Purity ◽  
Analytical Techniques ◽  
Full Potential ◽  
Labeled Compounds ◽  
Ph Adjustment ◽  
One Step ◽  
Stannous Ion ◽  
99Mtc Radiopharmaceuticals ◽  
Potential Use

SummaryThe full potential use of technetium has not been achieved despite its ideal physical properties, dosimetry and availability because of the complex preparations required for 99mTc radiopharmaceuticals. One of the goals of our work is to develop techniques for the preparation of high-purity 99mTc compounds which can be easily prepared, ideally by adding pertechnetate to a prepared solution.The use of stannous ion as reducing agent for technetium makes it possible to obtain such one-step, high-purity products. All non-radioactive components can be premixed in a single vial before addition of the radioactive pertechnetate. No final pH adjustment, further chemical manipulation or purification is required.Procedures for two instantly labeled compounds have been developed to date: 99mTc DTPA and 99mTc HSA. The 99mTc DTPA is prepared by adding pertechnetate to a previously prepared solution of stannous ion and CaNa3 DTPA which has been stored at pH 4. The 99mTc HSA is prepared by adding pertechnetate to a solution of stannous ion and HSA. The parametric variations and analytical techniques involved in formulating these procedures are described. It appears that development of kits for other biologically interesting compounds may be possible using similar procedures.

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

Sign in / Sign up

Export Citation Format

Share Document